Giuseppe
Emeritus
[Source: The Lancet, full text: (LINK). Abstract, edited.]
The Lancet, Volume 378, Issue 9788, Pages 360 - 368, 23 July 2011
doi:10.1016/S0140-6736(11)60440-6
Cite or Link Using DOI
Published Online: 09 June 2011
Vaccine discovery and translation of new vaccine technology
Original Text
Dr Rino Rappuoli PhD, Steven Black MD, Paul Henri Lambert MD
Summary
An unprecedented increase in new vaccine development has occurred over the past three decades. This activity has resulted in vaccines that protect against an increased range of vaccine-preventable diseases, vaccines that reduce the number of required injections, and vaccines with improved safety and purity. New methods of discovery, such as reverse vaccinology, structural biology, and systems biology, promise new vaccines for different diseases and efficient development pathways for these vaccines. We expect development of vaccines not only for infectious diseases in children but also for healthy adults, pregnant women, and elderly people, and for new indications such as autoimmune disease and cancer. We have witnessed a concomitant development of new technology for assessment of vaccine safety to rapidly identify potential safety issues. Success of these new approaches will depend on effective implementation of vaccination programmes, creative thinking on the part of manufacturers and regulators as to how best to ensure that safe and effective vaccines are available in a timely manner, and improvement of public awareness about the benefits and risks of new vaccines in a way that encourages confidence in vaccines.
- --------
The Lancet, Volume 378, Issue 9788, Pages 360 - 368, 23 July 2011
doi:10.1016/S0140-6736(11)60440-6
Cite or Link Using DOI
Published Online: 09 June 2011
Vaccine discovery and translation of new vaccine technology
Original Text
Dr Rino Rappuoli PhD, Steven Black MD, Paul Henri Lambert MD
Summary
An unprecedented increase in new vaccine development has occurred over the past three decades. This activity has resulted in vaccines that protect against an increased range of vaccine-preventable diseases, vaccines that reduce the number of required injections, and vaccines with improved safety and purity. New methods of discovery, such as reverse vaccinology, structural biology, and systems biology, promise new vaccines for different diseases and efficient development pathways for these vaccines. We expect development of vaccines not only for infectious diseases in children but also for healthy adults, pregnant women, and elderly people, and for new indications such as autoimmune disease and cancer. We have witnessed a concomitant development of new technology for assessment of vaccine safety to rapidly identify potential safety issues. Success of these new approaches will depend on effective implementation of vaccination programmes, creative thinking on the part of manufacturers and regulators as to how best to ensure that safe and effective vaccines are available in a timely manner, and improvement of public awareness about the benefits and risks of new vaccines in a way that encourages confidence in vaccines.